RG2133 (2',3',5'-tri-O-acetyluridine) ( DrugBank: Tri-O-acetyluridine )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 21 | ミトコンドリア病 | 1 |
21. ミトコンドリア病
臨床試験数 : 39 / 薬物数 : 42 - (DrugBank : 32) / 標的遺伝子数 : 47 - 標的パスウェイ数 : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00060515 (ClinicalTrials.gov) | April 2003 | 7/5/2003 | RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease | An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases | Mitochondrial Diseases | Drug: RG2133 (2',3',5'-tri-O-acetyluridine) | Repligen Corporation | NULL | Terminated | 3 Years | N/A | Both | 12 | Phase 1 | United States |